Results 151 to 160 of about 10,873 (203)
A Comparison of the Aldosterone-Blocking Agents Eplerenone and Spironolactone
Clinical Cardiology, 2008 Improved understand in g of the adverse pharmacological properties of aldosterone has prompted investigation of the clinical benefits of blocking aldosterone at the receptor level.
Henry Krum, Allan D. Struthers
exaly +2 more sources
Nature Reviews Drug Discovery, 2003 Data from animal studies and clinical trials indicate that aldosterone causes cardiovascular and renal injury through mineralocorticoid receptor–dependent mechanisms. However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific ...
Ruth, Brown +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Medical Ethics, 2012
The use of a placebo arm in clinical trials is unethical if there is an active comparator that is acceptably safe and effective. We argue that reasonable evidence of effectiveness and safety of an inexpensive alternative to an expensive therapy is sufficient to require that the inexpensive therapy be included as a comparator when the expensive therapy ...
Shruti, Gupta +2 more
openaire +2 more sources
The use of a placebo arm in clinical trials is unethical if there is an active comparator that is acceptably safe and effective. We argue that reasonable evidence of effectiveness and safety of an inexpensive alternative to an expensive therapy is sufficient to require that the inexpensive therapy be included as a comparator when the expensive therapy ...
Shruti, Gupta +2 more
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2004
Appreciation of the role of aldosterone in cardiovascular and renal disease has increased in the last 50 years. The use of spironolactone was limited by adverse sexual effects, including gynaecomastia. Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore ...
openaire +2 more sources
Appreciation of the role of aldosterone in cardiovascular and renal disease has increased in the last 50 years. The use of spironolactone was limited by adverse sexual effects, including gynaecomastia. Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore ...
openaire +2 more sources
Current opinion in investigational drugs (London, England : 2000), 2003
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on ...
Liew, Danny +2 more
openaire +2 more sources
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on ...
Liew, Danny +2 more
openaire +2 more sources
American Journal of Cardiovascular Drugs, 2005
Eplerenone is a selective aldosterone blocker (SAB) approved for the treatment of essential hypertension. Oral eplerenone reduced BP effectively in patients with essential hypertension, both as monotherapy and in combination with other agents. The drug is generally well tolerated; the risk of hyperkalemia can be managed through careful selection and ...
Katherine F, Croom, Caroline M, Perry
openaire +2 more sources
Eplerenone is a selective aldosterone blocker (SAB) approved for the treatment of essential hypertension. Oral eplerenone reduced BP effectively in patients with essential hypertension, both as monotherapy and in combination with other agents. The drug is generally well tolerated; the risk of hyperkalemia can be managed through careful selection and ...
Katherine F, Croom, Caroline M, Perry
openaire +2 more sources
The Clinical Pharmacology of Eplerenone
Expert Opinion on Drug Metabolism and Toxicology, 2009Eplerenone is an aldosterone receptor antagonist indicated for the treatment of hypertension and congestive heart failure. Eplerenone contains an epoxy group, which offers greater mineralocorticoid receptor specificity. It is an effective antihypertensive that has been shown to reduce morbidity and mortality in individuals with left ventricular ...
James A, Muldowney +2 more
exaly +3 more sources
Eplerenone for the treatment of cardiovascular disorders
Expert Review of Cardiovascular Therapy, 2012The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone ...
Masataka, Watanabe, Henry, Krum
openaire +2 more sources
▼Eplerenone after myocardial infarction?
Drug and Therapeutics Bulletin, 2008Each year in the UK, an estimated 50,000 patients develop major left ventricular systolic dysfunction (LVSD) and heart failure following a myocardial infarct.1 Such patients have a particularly poor prognosis.2 ▼Eplerenone (Inspra – Pfizer) is an aldosterone-receptor antagonist for patients who have LVSD and heart failure following a recent myocardial ...
openaire +2 more sources